Eleftherios Diamandis

Summary

Affiliation: Mount Sinai Hospital
Country: Canada

Publications

  1. ncbi request reprint Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids
    Christina V Obiezu
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Chem 51:1432-42. 2005
  2. pmc Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9
    Shalini Makawita
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    BMC Cancer 13:404. 2013
  3. doi request reprint Nobelitis: a common disease among Nobel laureates?
    Eleftherios P Diamandis
    Mount Sinai Hospital, Department of Pathology and Laboratory Medicine, ACDC Laboratory, 6th floor Room L6 201, 60 Murray Street, PO Box 32, Toronto, ON, M5T 3L9, Canada
    Clin Chem Lab Med 51:1573-4. 2013
  4. pmc The sweet and sour of serological glycoprotein tumor biomarker quantification
    Uros Kuzmanov
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, 6th Floor, 60 Murray Street, Box 32, Toronto, ON M5T 3L9, Canada
    BMC Med 11:31. 2013
  5. pmc Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains
    Ilijana Begčević
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    Clin Proteomics 10:5. 2013
  6. pmc Fascin-1 is a novel biomarker of aggressiveness in some carcinomas
    Vathany Kulasingam
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    BMC Med 11:53. 2013
  7. pmc Quantitative proteomic analysis of amniocytes reveals potentially dysregulated molecular networks in Down syndrome
    Chan Kyung J Cho
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    Clin Proteomics 10:2. 2013
  8. doi request reprint Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue
    George S Karagiannis
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada
    Mol Cancer Res 10:1403-18. 2012
  9. doi request reprint Revisiting the complexity of the ovarian cancer microenvironment--clinical implications for treatment strategies
    Natasha Musrap
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Joseph and Wolf Lebovic Complex, Toronto, ON, Canada M5T 3L9
    Mol Cancer Res 10:1254-64. 2012
  10. pmc The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    BMC Med 10:87. 2012

Research Grants

  1. Human Kallikrein 4 (hK4): A New Prostatic Biomarker?
    Eleftherios Diamandis; Fiscal Year: 2003
  2. A New Biomarker for Ovarian Cancer Detection
    Eleftherios Diamandis; Fiscal Year: 2003
  3. KALLIKREINS AS DIAGNOSTIC MARKERS OF OVARIAN CARCINOMA
    Eleftherios Diamandis; Fiscal Year: 2007

Detail Information

Publications97

  1. ncbi request reprint Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids
    Christina V Obiezu
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Chem 51:1432-42. 2005
    ....
  2. pmc Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9
    Shalini Makawita
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    BMC Cancer 13:404. 2013
    ..The present study details further validation of four of our previously identified candidates: regenerating islet-derived 1 beta (REG1B), syncollin (SYCN), anterior gradient homolog 2 protein (AGR2), and lysyl oxidase-like 2 (LOXL2)...
  3. doi request reprint Nobelitis: a common disease among Nobel laureates?
    Eleftherios P Diamandis
    Mount Sinai Hospital, Department of Pathology and Laboratory Medicine, ACDC Laboratory, 6th floor Room L6 201, 60 Murray Street, PO Box 32, Toronto, ON, M5T 3L9, Canada
    Clin Chem Lab Med 51:1573-4. 2013
    ..Since Nobels are awarded when the laureates have usually passed their prime, caution should be exercised when these individuals are offered highly influential positions in academia and elsewhere...
  4. pmc The sweet and sour of serological glycoprotein tumor biomarker quantification
    Uros Kuzmanov
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, 6th Floor, 60 Murray Street, Box 32, Toronto, ON M5T 3L9, Canada
    BMC Med 11:31. 2013
    ....
  5. pmc Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer's disease and age-matched control brains
    Ilijana Begčević
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    Clin Proteomics 10:5. 2013
    ..High-throughput proteomic and pathway analysis of hippocampal tissue provides a valuable source of disease-related proteins and biomarker candidates, since it represents one of the earliest affected brain regions in AD...
  6. pmc Fascin-1 is a novel biomarker of aggressiveness in some carcinomas
    Vathany Kulasingam
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    BMC Med 11:53. 2013
    ..Please see related research article here http://www.biomedcentral.com/1741-7015/11/52...
  7. pmc Quantitative proteomic analysis of amniocytes reveals potentially dysregulated molecular networks in Down syndrome
    Chan Kyung J Cho
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    Clin Proteomics 10:2. 2013
    ....
  8. doi request reprint Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue
    George S Karagiannis
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada
    Mol Cancer Res 10:1403-18. 2012
    ..Not only does it provide essential signals for cancer cell dedifferentiation, proliferation, and survival but it also facilitates cancer cell local invasion and metastatic phenomena...
  9. doi request reprint Revisiting the complexity of the ovarian cancer microenvironment--clinical implications for treatment strategies
    Natasha Musrap
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Joseph and Wolf Lebovic Complex, Toronto, ON, Canada M5T 3L9
    Mol Cancer Res 10:1254-64. 2012
    ..Herein, an overview of the varying tumor-host interactions that influence tumor behavior will be discussed, in addition to the recent efforts undertaken to target these interactions and their potential to revolutionize EOC patient care...
  10. pmc The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    BMC Med 10:87. 2012
    ..I further provide examples of combinations of some known cancer biomarkers that can perform well in niche clinical applications, despite individually being not useful...
  11. pmc Characterization of the seminal plasma proteome in men with prostatitis by mass spectrometry
    Daniel Kagedan
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
    Clin Proteomics 9:2. 2012
    ..abstract:..
  12. pmc Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery
    Ioannis Prassas
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    BMC Med 10:39. 2012
    ..Current biomarkers suffer from a lack of tissue specificity, rendering them vulnerable to non-disease-specific increases. The present study details a strategy to rapidly identify tissue-specific proteins using bioinformatics...
  13. ncbi request reprint Prostate-specific antigen: a cancer fighter and a valuable messenger?
    E P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Chem 46:896-900. 2000
    ..Despite the voluminous literature on this biomarker, relatively few reports have addressed the issue of its physiological function and its connection to the pathogenesis and progression of prostate and other cancers...
  14. ncbi request reprint Peptidomics for cancer diagnosis: present and future
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Proteome Res 5:2079-82. 2006
    ..Before this technology is used clinically, it is important to understand its advantages and limitations. These are summarized, along with proposals, on how to proceed in the future...
  15. ncbi request reprint Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Cancer Res 66:5540-1. 2006
  16. ncbi request reprint Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G 1X5 Canada
    Clin Chem 49:1272-5. 2003
  17. ncbi request reprint Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, M5G 1X5, Canada
    Clin Biochem 37:823-9. 2004
    ..Our preliminary studies indicate that hK11 may represent a diagnostic and prognostic biomarker for ovarian cancer. The aim of the present study was to examine the prognostic value of hK11 expression in ovarian tumors...
  18. ncbi request reprint An update on human and mouse glandular kallikreins
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
    Clin Biochem 37:258-60. 2004
    ..Here, we describe an update of the genomic organization of these families in human and mouse, and provide some thoughts for future research directions...
  19. ncbi request reprint Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Natl Cancer Inst 96:353-6. 2004
  20. ncbi request reprint Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
    Mol Cell Proteomics 3:367-78. 2004
    ..It is clear that the method needs to be externally and thoroughly validated before clinical implementation is warranted...
  21. pmc Cancer biomarkers: can we turn recent failures into success?
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 60 Murray St, Rm L6 201, Toronto, ON, Canada M5T 3L9
    J Natl Cancer Inst 102:1462-7. 2010
    ....
  22. doi request reprint Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks
    Ioannis Prassas
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada
    Mol Cancer Ther 10:2083-93. 2011
    ..Hence, our findings provide more in-depth information regarding the molecular mechanisms underlying cardiac glycoside-induced cytotoxicity...
  23. ncbi request reprint Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications
    E P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada
    Clin Biochem 33:369-75. 2000
    ..One new member is the KLK6 gene, encoding for human kallikrein 6 (hK6), which is also known as zyme/protease M/neurosin. In this paper, we describe development of antibodies and a sensitive immunofluorometric procedure for hK6 protein...
  24. ncbi request reprint Human kallikrein 6 as a biomarker of alzheimer's disease
    E P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada
    Clin Biochem 33:663-7. 2000
    ..Our aim was to examine the possible use of cerebrospinal fluid, blood and tissue, and human kallikrein 6 (hK6) concentration as a marker of AD...
  25. ncbi request reprint Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5 Canada
    Cancer Res 62:295-300. 2002
    ..This is the first reported immunological assay for hK11. Analysis of this biomarker in serum may aid in the diagnosis and monitoring of ovarian and prostatic carcinoma...
  26. ncbi request reprint Human tissue kallikrein gene family: a rich source of novel disease biomarkers
    E P Diamandis
    Dept of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada
    Expert Rev Mol Diagn 1:182-90. 2001
    ..In this review, we examine the diagnostic and prognostic value of the 15 human kallikrein genes and proteins. It is clear that at least a few members show promise of becoming novel cancer and other disease biomarkers...
  27. ncbi request reprint Duties and responsibilities of laboratory scientists
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Chim Acta 319:111-5. 2002
    ..The new developments in science and technology suggest that we are yet to realize the best times of this exciting profession...
  28. ncbi request reprint Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
    Clin Biochem 37:230-7. 2004
    ..Some of these enzymes can be measured in cerebrospinal fluid (CSF) by using ELISA-type methodologies...
  29. ncbi request reprint Human tissue kallikreins: a family of new cancer biomarkers
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Chem 48:1198-205. 2002
    ..In addition to their diagnostic/prognostic potential, kallikreins may also emerge as attractive targets for therapeutics...
  30. doi request reprint Pentraxin-3 is a novel biomarker of lung carcinoma
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 17:2395-9. 2011
    ..Our objective was to validate the performance of three new candidate lung cancer biomarkers, pentraxin-3 (PTX3), human kallikrein 11 (KLK11), and progranulin...
  31. ncbi request reprint Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 21:1035-43. 2003
    ..The discovery of new ovarian cancer biomarkers that are suitable for early disease diagnosis and prognosis may ultimately lead to improved patient management and outcomes...
  32. ncbi request reprint Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium
    Girish Sardana
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    Clin Chem 53:429-37. 2007
    ..Additional tumor markers are needed for the early detection of clinically relevant CaP. Our objective was to perform a qualitative proteomic analysis of conditioned medium (CM) from the CaP cell line PC3(AR)(6)...
  33. ncbi request reprint Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay
    Carl Kapadia
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5 Canada
    Clin Chem 49:77-86. 2003
    ..The aims of this study were to develop immunologic reagents and a sensitive and specific immunoassay for human kallikrein 13 (hK13) and to examine the presence of hK13 in human tissues and biological fluids...
  34. ncbi request reprint Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids
    Julie L V Shaw
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada, M5G 1X5
    Clin Biochem 40:104-10. 2007
    ..The assay was then used to examine levels of KLK15 in tissues and biological fluids...
  35. ncbi request reprint Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14
    Carla A Borgono
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada
    J Biol Chem 282:2405-22. 2007
    ..These findings may have clinical implications for the management of cancer and other disorders in which KLK14 activity is elevated...
  36. ncbi request reprint Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry
    Christina V Obiezu
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, M5G 1X5 Canada
    Clin Chem 48:1232-40. 2002
    ..Because the protein has not been detected in any human tissue, we attempted to develop immunologic methods for hK4 analysis and use them to detect hK4 in healthy and cancerous tissue extracts and biological fluids...
  37. ncbi request reprint Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer
    George M Yousef
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5 Canada
    Cancer Res 63:3958-65. 2003
    ..Our preliminary data indicate that hK5 is a potential biomarker in patients with ovarian and breast cancer...
  38. ncbi request reprint The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer
    George M Yousef
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Breast Cancer Res Treat 78:149-58. 2003
    ..Like other kallikreins, the KLK9 gene was found to be regulated by steroid hormones, mainly estrogens and progestins, in cancer cell lines...
  39. doi request reprint Emerging biomarkers for the diagnosis and prognosis of prostate cancer
    Girish Sardana
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Clin Chem 54:1951-60. 2008
    ..Prostate-specific antigen (PSA) testing is a significant advance for early diagnosis of patients with CaP...
  40. doi request reprint The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer
    Girish Sardana
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
    Clin Biochem 42:1483-6. 2009
    ..Here we examine the clinical utility of multiple members of the kallikrein family of proteins in non-manipulative urinary biomarker testing...
  41. ncbi request reprint Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids
    Tadaaki Kishi
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5 Canada
    Clin Chem 49:87-96. 2003
    ..The aim of this study was to develop a sensitive and specific immunoassay for hK8 (hK8-ELISA) and establish the distribution of hK8 in tissue extracts and biological fluids...
  42. ncbi request reprint Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma
    Carla A Borgono
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Int J Cancer 106:605-10. 2003
    ..These results indicate that hK11 is a novel, independent marker of favorable prognosis in patients with ovarian cancer...
  43. ncbi request reprint Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols
    Shannon J C Shan
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    Clin Chem 52:1879-86. 2006
    ..The aim of this study was to determine whether hK7, measured quantitatively by ELISA in ovarian cancer cytosols, is a prognostic biomarker for ovarian cancer...
  44. ncbi request reprint Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues
    George M Yousef
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
    Prostate 56:287-92. 2003
    ..Since KLK14 was found to be regulated by steroid hormones in prostate cancer cell lines, we hypothesized that it will be differentially expressed in prostate cancer tissues compared to their normal counterparts...
  45. ncbi request reprint Human kallikrein 8, a novel biomarker for ovarian carcinoma
    Tadaaki Kishi
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada
    Cancer Res 63:2771-4. 2003
    ..These data suggest that hK8 protein is detectable in ovarian cancer tissue extracts, serum, and ascites fluid, indicating that it may serve as a new ovarian cancer marker...
  46. ncbi request reprint Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer
    Carla A Borgono
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Ontario, Canada
    Clin Cancer Res 12:1487-93. 2006
    ..001 and P = 0.014, respectively). These results indicate that hK8 is an independent marker of favorable prognosis in ovarian cancer...
  47. ncbi request reprint Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma
    Liu Ying Luo
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 12:742-50. 2006
    ..Preliminary data suggest that hK11 is a novel serum biomarker for prostate and ovarian cancer. To examine the enzymatic characteristics of hK11, we purified and functionally characterized native hK11 from seminal plasma...
  48. doi request reprint Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers
    Girish Sardana
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    J Proteome Res 7:3329-38. 2008
    ....
  49. ncbi request reprint The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis
    Liu Ying Luo
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5 Canada
    Cancer Res 63:807-11. 2003
    ..Serum hK10 represents a novel biomarker for ovarian cancer. We conclude that preoperative serum hK10 concentration is a strong and independent unfavorable prognostic marker for ovarian cancer...
  50. ncbi request reprint Human kallikrein 14: a new potential biomarker for ovarian and breast cancer
    Carla A Borgono
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Cancer Res 63:9032-41. 2003
    ..Our preliminary data indicate that hK14 is a potential biomarker for breast and ovarian cancers...
  51. ncbi request reprint Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer
    George M Yousef
    Dept of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, Canada M5G 1X5
    Am J Clin Pathol 119:346-55. 2003
    ..43 and 0.53; P = .027 and .014). A weak negative correlation was found between KLK14 expression and serum CA-125. KLK14 is a new, independent, and favorable prognostic marker for ovarian cancer...
  52. ncbi request reprint Intron retention: a common splicing event within the human kallikrein gene family
    Iacovos P Michael
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Clin Chem 51:506-15. 2005
    ..Given that introns <100 bp in length are retained in 95% of human genes and that splice variants of KLK3 and KLK4 retain intron III, we hypothesized that other proteins in this family, with a small intron III, may also retain it...
  53. ncbi request reprint Prognostic value of the human kallikrein gene 15 expression in ovarian cancer
    George M Yousef
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada
    J Clin Oncol 21:3119-26. 2003
    ..KLK15 is upregulated mainly by androgens and to a lesser extent by progestins. The purpose of this study was to examine the prognostic value of KLK15 in ovarian cancer tissues...
  54. ncbi request reprint Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients
    Maryam Zarghooni
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada
    Clin Biochem 35:225-31. 2002
    ..Our objective was to develop a highly sensitive immunoassay for hK6 and use it to examine the levels of hK6 in brain tissue extracts from Alzheimer's disease patients and control subjects...
  55. ncbi request reprint Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer
    Lianna G Kyriakopoulou
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, M5G 1X5 Canada
    Clin Biochem 36:135-43. 2003
    ..Recent evidence has indicated that expression of KLK7 appears to be increased in ovarian cancer. We hypothesized that overexpression of the KLK7 gene in ovarian cancer may serve as a prognostic marker of the disease...
  56. ncbi request reprint Mass spectrometry: uncovering the cancer proteome for diagnostics
    Da elene van der Merwe
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G1X5, Canada
    Adv Cancer Res 96:23-50. 2007
    ..It is essential that research groups, the industry, and physicians collaborate to conduct large prospective, multicenter clinical trials to validate and standardize this technology, for it to have real clinical impact...
  57. doi request reprint Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs
    Nicole M White
    Department of Laboratory Medicine and the Keenan Research Center in the Li Ka Shing Knowledge Institute, St Michael s Hospital, Toronto, Ontario, Canada
    Biol Chem 391:411-23. 2010
    ..The observation that KLKs could represent targets for miRNAs suggests a post-transcriptional regulatory mechanism with possible future therapeutic applications...
  58. ncbi request reprint Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues
    Terukazu Nakamura
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Urology 61:1042-6. 2003
    ..4. Hippostasin has two alternative splicing isoforms, known as the brain type and prostate type. We have previously reported that the prostate-type isoform is not expressed in human prostate cancer cell lines...
  59. ncbi request reprint Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers
    Bhupinder B Bharaj
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Prostate 51:35-41. 2002
    ..KLK10 is also upregulated in ovarian cancer. We thus hypothesized that the KLK10 gene may be a target for mutations in various cancers...
  60. doi request reprint Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression
    Miltiadis Paliouras
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ont, Canada
    Tumour Biol 29:63-75. 2008
    ..Our aim was to examine how certain signal transduction pathways influence the regulation of hormone-dependent kallikrein (KLK) gene expression in androgen-sensitive breast cancer cell lines...
  61. doi request reprint Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer
    C Geeth Gunawardana
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    J Proteome Res 8:4705-13. 2009
    ..We conclude that in-depth proteomic analysis of cell culture supernatants of ovarian cancer cell lines can identify potential ovarian cancer biomarkers that are worth further clinical validation...
  62. pmc Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers
    Cynthia Kuk
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 1L5, Canada
    Mol Cell Proteomics 8:661-9. 2009
    ..Our proteomics approach for discovering novel ovarian cancer biomarkers appears to be highly efficient because it was able to identify 25 known biomarkers and 52 new candidate biomarkers that warrant further validation...
  63. doi request reprint Androgens act synergistically to enhance estrogen-induced upregulation of human tissue kallikreins 10, 11, and 14 in breast cancer cells via a membrane bound androgen receptor
    Miltiadis Paliouras
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    Mol Oncol 1:413-24. 2008
    ..The synergistic effects between estrogens and androgens on estrogen-sensitive genes may have implications on the role of the kallikreins in associated risk of breast cancer and progression...
  64. ncbi request reprint Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues
    George M Yousef
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada
    Prostate 51:126-32. 2002
    ..4. Like KLK2 and KLK3, the KLK5 gene is regulated by steroid hormones in the BT-474 breast cancer cell line. We have previously shown that KLK5 is differentially expressed in ovarian and breast cancer...
  65. ncbi request reprint Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
    Tumour Biol 24:299-309. 2003
    ..297; p < 0.001). Our findings provide evidence for an association between hK5 and more aggressive forms of epithelial ovarian cancer...
  66. ncbi request reprint Collecting duct carcinoma associated with oncocytoma
    George M Yousef
    Memorial University, St John s, Canada
    Int Braz J Urol 31:465-7; discussion 467-9. 2005
    ..Identification and reporting CDC is important for the establishment of treatment strategies and monitoring prognosis...
  67. ncbi request reprint Kallikreins as markers of disseminated tumour cells in ovarian cancer-- a pilot study
    Katerina Oikonomopoulou
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
    Tumour Biol 27:104-14. 2006
    ..We hypothesized that KLK6 and KLK10 can be utilized to monitor dissemination of ovarian cancer cells in blood and ascites fluid of ovarian cancer patients...
  68. ncbi request reprint Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids
    Tadaaki Kishi
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Chem 50:709-16. 2004
    ..The aim of this study was to develop a sensitive and specific immunoassay for hK7 and to examine the distribution of hK7 in tissue extracts and biological fluids...
  69. ncbi request reprint Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer
    Lisa Kurlender
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
    Tumour Biol 25:149-56. 2004
    ..KLK5-SV1 may have clinical utility in various malignancies and should be further explored as a potential new biomarker for prostate and ovarian cancer...
  70. ncbi request reprint Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection
    Robert K Nam
    Division of Urology, 2075 Bayview Ave, MG 406, Toronto, Ontario, Canada, M4N 3M5
    J Clin Oncol 21:2312-9. 2003
    ..We examined the relationship between a mutant (T) for wild-type (C) allele substitution of the human kallikrein-2 gene (KLK2), circulating human kallikrein-2 (hK2) levels and prostate cancer risk...
  71. ncbi request reprint The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia
    Terukazu Nakamura
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada
    Cancer Res 63:6543-6. 2003
    ..69). These preliminary data suggest that the hK11:total PSA ratio could be a useful tumor marker for CaP and could be combined with percentage of PSA to further reduce the number of unnecessary prostatic biopsies...
  72. ncbi request reprint Complex formation between human kallikrein 13 and serum protease inhibitors
    Carl Kapadia
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5
    Clin Chim Acta 339:157-67. 2004
    ..Given that other kallikreins are sequestered by serum protease inhibitors, we hypothesized that hK13 may also interact with similar inhibitors. Our objective was to identify serum protease inhibitors that interact with human hK13...
  73. pmc Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines
    Chris Planque
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G1X5, Canada
    Mol Cell Proteomics 8:2746-58. 2009
    ..Our results demonstrate the utility of this cell culture proteomics approach to identify secreted and shed proteins that are potentially useful as serological markers for lung cancer...
  74. ncbi request reprint Human tissue kallikrein gene family: applications in cancer
    Christina V Obiezu
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ont, Canada M5G 1X5
    Cancer Lett 224:1-22. 2005
    ..We here review the evidence linking kallikreins and cancer and their applicability as novel biomarkers for cancer diagnosis and management...
  75. ncbi request reprint Tissue kallikreins: new players in normal and abnormal cell growth?
    George M Yousef
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Thromb Haemost 90:7-16. 2003
    ..For example, hK6, 10 and 11 are promising serological markers for ovarian cancer diagnosis. KLK10 may act as a tumor suppressor. In addition to their diagnostic and prognostic values, kallikreins may also be good therapeutic targets...
  76. doi request reprint Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: their relation to sperm motility
    Nashmil Emami
    Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada
    Biol Chem 390:921-9. 2009
    ..In conclusion, the expression level of several seminal plasma KLKs correlates with liquefaction and viscosity indicators of semen quality and may aid in their differential diagnosis and etiology...
  77. ncbi request reprint Human tissue kallikreins: from gene structure to function and clinical applications
    George M Yousef
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada
    Adv Clin Chem 39:11-79. 2005
  78. ncbi request reprint Human kallikrein-related peptidase 12: antibody generation and immunohistochemical localization in prostatic tissues
    Nader Memari
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Prostate 67:1465-74. 2007
    ..Here, we report generation of antibodies against the full-length recombinant KLK12 (classical form) and the immunohistological localization of this KLK in normal and malignant prostate tissues...
  79. ncbi request reprint High throughput proteomic strategies for identifying tumour-associated antigens
    C Geeth Gunawardana
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ont, Canada
    Cancer Lett 249:110-9. 2007
    ..In this mini-review, we aim to describe these three techniques and provide their advantages and disadvantages. In addition, we aim to address some of the challenges of cancer immunomics...
  80. ncbi request reprint Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers
    Michael Sidiropoulos
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
    Tumour Biol 26:324-36. 2005
    ..Recently, it has been shown that CpG island hypermethylation of the KLK10 gene is responsible for the tumor-specific loss of KLK10 gene expression in certain breast cancer cell lines...
  81. ncbi request reprint Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA
    Andreas Scorilas
    National Center for Scientific Research Demokritos, IPC, Athens, Greece
    Prostate 54:220-9. 2003
    ....
  82. ncbi request reprint Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma
    Maroulio Talieri
    G Papanicolaou Research Center of Oncology, Saint Savas Hospital, Athens Greece
    Thromb Haemost 91:180-6. 2004
    ..These data suggest that KLK7 gene expression may be used as a marker of unfavorable prognosis for breast cancer patients...
  83. ncbi request reprint Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker
    Andreas Scorilas
    Department of Biochemistry and Molecular Biology, University of Athens, Greece
    J Clin Oncol 22:678-85. 2004
    ..We hypothesized that hK13 may represent a potential biomarker for ovarian carcinomas...
  84. ncbi request reprint Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network
    Carsten Stephan
    Department of Urology, University Hospital Charite Berlin, Berlin, Germany
    Prostate 66:651-9. 2006
    ....
  85. ncbi request reprint Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer
    Carsten Stephan
    Department of Urology, University Hospital Charite Berlin, Berlin, Germany
    Int J Urol 13:238-43. 2006
    ..We investigated the role of hK2 serum values for predicting pathological stage, grade and Gleason score...
  86. ncbi request reprint Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer
    Carsten Stephan
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Berlin, Germany
    Urology 59:2-8. 2002
  87. ncbi request reprint Potential markers that complement expression of CA125 in epithelial ovarian cancer
    Daniel G Rosen
    Department of Pathology, University of Texas M D Anderson Cancer Center, Box 355, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 99:267-77. 2005
    ..Serum tumor markers that can be detected in ovarian cancers that lack CA125 expression might improve the sensitivity for early detection...
  88. ncbi request reprint Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma
    Martin W McIntosh
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 13:4422-8. 2007
    ..The human kallikrein 11 (hK11) marker has been reported to have favorable predictive value for ovarian cancer, although, by itself, it may be inferior to CA 125...
  89. ncbi request reprint Re: Serum proteomic patterns for detection of prostate cancer
    Eleftherios P Diamandis
    J Natl Cancer Inst 95:489-90; author reply 490-1. 2003
  90. ncbi request reprint Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer
    Edward R Sauter
    Department of Surgery, University of Missouri Columbia, M588 Health Sciences Center, One Hospital Drive, Columbia, MO 65212, USA
    Cancer Detect Prev 28:27-31. 2004
    ..009), nodal status (P = 0.005), disease stage (P = 0.004), and distant metastases (P = 0.04). NAF PSA provides useful prognostic information which may assist with breast cancer treatment...
  91. ncbi request reprint Association of kallikrein expression in nipple aspirate fluid with breast cancer risk
    Edward R Sauter
    Department of Surgery, University of Missouri, Columbia, MO 65212, USA
    Int J Cancer 108:588-91. 2004
    ..hK2 and PSA, and hK6 and hK10 are highly associated. Higher premenopausal PSA levels suggest the influence of ovarian steroids. PSA shows the most promise in aiding in the early detection of breast cancer...
  92. ncbi request reprint Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin
    Shirley Hutchinson
    Department of Pathology, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5 Canada
    Clin Chem 49:746-51. 2003
    ..Human kallikrein 6 (hK6) is significantly increased in serum in many patients with ovarian cancer and may have a role in amyloid precursor processing and Alzheimer disease. The forms of hK6 in biological fluids are poorly characterized...
  93. ncbi request reprint POINT: EPCA-2: a promising new serum biomarker for prostatic carcinoma?
    Eleftherios P Diamandis
    Clin Biochem 40:1437-9. 2007
  94. ncbi request reprint Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma
    Constantina D Petraki
    Department of Pathology, Evangelismos Hospital, Athens, Greece
    Tumour Biol 27:1-7. 2006
    ....
  95. ncbi request reprint An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers
    George M Yousef
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Biochem 36:443-52. 2003
    ..Of special interest is the potential role of kallikreins in the central nervous system. In addition, many kallikreins seem to be candidate tumor markers for many malignancies, especially those of endocrine-related organs...
  96. ncbi request reprint Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection
    Carsten Stephan
    Department of Urology, Univeristy Hospital Charité, Berlin, Germany
    BJU Int 96:521-7. 2005
    ....
  97. ncbi request reprint A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy
    Yingye Zheng
    The Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Cancer Res 13:6984-92. 2007
    ....

Research Grants5

  1. Human Kallikrein 4 (hK4): A New Prostatic Biomarker?
    Eleftherios Diamandis; Fiscal Year: 2003
    ..If successful, our research will contribute to the development of new prostatic biomarkers and possibly, to better diagnosis which may lead to better clinical outcomes and reduced healthcare costs. ..
  2. A New Biomarker for Ovarian Cancer Detection
    Eleftherios Diamandis; Fiscal Year: 2003
    ..In this grant proposal, we describe further studies, which will examine in greater detail, the ability of a test for the amount of this protein in blood to correctly diagnose the presence of ovarian cancer. ..
  3. KALLIKREINS AS DIAGNOSTIC MARKERS OF OVARIAN CARCINOMA
    Eleftherios Diamandis; Fiscal Year: 2007
    ..Relevance of this research to public health: By achieving early ovarian cancer diagnosis, it will be possible to reduce the burden of the disease by administration of effective treatment as early as possible. ..